Introduction
In recent years, aldosterone has attracted attention as a cardiovascular risk factor, and it has been shown that an inappropriate balance between aldosterone and salt raises blood pressure, and directly causes organ damage through various mechanisms. [1] [2] [3] [4] [5] Both the Randomized Aldactone Evaluation Study (RALES) and the Eplerenone Post-AMI Heart Failure Efficacy and Survival Study (EPHESUS) found that mortality, risk of hospitalization and the onset of cardiovascular events decreased significantly after adding the administration of mineralocorticoid receptor (MR) antagonist, spironolactone or eplerenone, in patients with severe heart failure, and following acute myocardial infarction complicated with left ventricular dysfunction. 6, 7 These studies have had a major impact in this field, and have contributed to a rapid increase in the volume of MR antagonist prescribed for treating heart failure. We have reported that the MR antagonist is also effective for patients with chronic kidney diseases, with or without type 2 diabetes. 8, 9 Although only its organ-protective effects tended to attract clinical attention, the MR antagonist is an efficient antihypertensive drug targeting the aldosterone effect. Spironolactone is the first anti-aldosterone agent developed. Spironolactone is a potent MR antagonist, and has a stable antihypertensive effect. However, it also causes dose-dependent endocrine adverse events, including gynecomastia, menstrual irregularity and breast pain due to its low MR selectivity, 10 such that is not possible to use a sufficient dose to achieve the optimal antihypertensive effect. Therefore, it is mainly used at lower doses to treat cardiac failure or to control ascites due to hepatic cirrhosis. Spironolactone is useful as an additional drug for treatment-resistant hypertension.
11 The Anglo-Scandinavian Cardiac Outcome Trial-Blood Pressure Lowering Arm (AS-COT-BPLA) used spironolactone as the fourth drug and it was proven to be effective. 12 In 2007, eplerenone, a selective aldosterone blocker, became clinically available in Japan. Currently, eplerenone is indicated for heart failure in 460 countries based on its anticipated beneficial cardiac effect. 7 It has been reported that eplerenone also has a stable antihypertensive effect, [13] [14] [15] [16] [17] [18] [19] [20] with a profile slightly different from that of spironolactone, 21 and fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension. However, clinical data on hypertensive patients in Japan are lacking for eplerenone. 22 Given this background, we explored the clinical efficacy of eplerenone when it is added to an angiotensinconverting enzyme (ACE) inhibitor or a long-acting calcium channel blocker (CCB) in Japanese patients with essential hypertension.
Subjects and methods
In all, 68 patients (31 males, 37 females, mean age: 63 ± 10 years) with essential hypertension, who visited the International University of Health and Welfare Mita Hospital (Tokyo, Japan), and who had been treated with an ACE inhibitor (imidapril, average dose 6.0 mg, 54 patients) or a long-acting CCB (amlodipine, average dose 6.6 mg, 14 patients) without achieving their target blood pressure were enrolled in this study. Blood pressure before monotherapy with imidapril or amlodipine was 166 ± 12/100 ± 7 mm Hg. The target blood pressure in monotherapy is under 140/90 mm Hg, on the basis of the Guidelines for the Management of Hypertension 2004 by the Japanese Society of Hypertension. Screening for secondary hypertension was conducted, and confirmed to be absent in all patients before starting antihypertensive treatment.
As eplerenone is contraindicated in the presence of hyperkalemia (X5.0 mEq l À1 ), moderate or severe renal impairment (creatinine clearance o50 ml/min), and diabetes with microalbuminuria or proteinuria, patients with these conditions were excluded from this study. When patients were confirmed not to have other contraindications for eplerenone, they received 50 mg of eplerenone once every morning in addition to their regular treatment. The eplerenone dose was maintained at 50 mg throughout the study. Follow-up outpatient visits were scheduled at 2 weeks after starting eplerenone treatment, and then every 4 weeks for 24 weeks of treatment.
Blood pressure was measured in a sitting position at rest in the outpatient clinic as previously reported. 8, 9 The mean of two stable values was taken as the blood pressure value. Radial artery pulse was measured over 30 seconds. Tests including general biochemistry, plasma renin activity (PRA), plasma aldosterone concentration (PAC), urinary albumin excretion (revised by creatinine value; UAE, mg g À1 Cr), brain natriuretic peptide and high-sensitivity C-reactive protein were conducted before and after eplerenone treatment. The assay sensitivity for PRA was 0.1-20 ng ml À1 h À1 (renin activity, TFB, Corporation) and for PAC it was 25-1600 pg ml À1 (SPAC-S Aldosterone Kit, Dai-ichi Radio-isotope).
Among all subjects, 16 (10 males, 6 females) met the diagnostic criteria for metabolic syndrome before monotherapy with imidapril or amlodipine. Metabolic syndrome was diagnosed according to the criteria established by the Examination Committee of Criteria for Metabolic Syndrome in Japan. Metabolic syndrome is defined for subjects with a waist circumference of X85 cm in men and X90 cm in women (essential criteria), and with at least two of the following three factors: serum triglycerides X150 mg per 100 ml and/or high-density lipoprotein cholesterol o40 mg per 100 ml, systolic blood pressure X130 mm Hg and/or diastolic blood pressure X85 mm Hg, fasting plasma glucose X110 mm Hg. We provided these patients with antihypertensive therapy while continuing to instruct them to change their lifestyles, including exercise and diet, which aimed at reducing the accumulation of visceral fat.
Measurements are presented as means ± s.d. Statistical significance was evaluated by one-way or two-way analysis of variance with repeated measures, as appropriate. The two-group paired ttest was used to test the significance of differences between pairs of groups with the level of significance being o5%. Pearson's correlation coefficient was used to determine correlation coefficients.
Results
Clinical and biological data for all patients before and after eplerenone treatment Table 1 shows the background characteristics of the patients and clinical data, before and 24 weeks after treatment with eplerenone. All patients had already received 4-8 weeks of treatment with either imidapril or amlodipine, but their blood pressures averaged 157 ± 11/94 ± 6 mm Hg, and had not reached the target value. After adding 50 mg of eplerenone to their basal treatment, blood pressure was significantly reduced to 141 ± 9/83 ± 7 mm Hg at 4 weeks, and further reduced to 130±6/ 76 ± 5 mm Hg after 24 weeks of eplerenone treatment ( Figure 1 ). PRA and PAC increased significantly with treatment (PRA; from 1.87±1.10 to 3.33± 2.56 ng ml À1 h À1 , PAC; from 94.0±31.9 to 114.4± 39.8 pg ml À1 , Figure 2 ). UAE (193.8 ± 397.7 mg g
À1
Cr; before treatment with eplerenone) decreased significantly after 12 weeks, and further decreased to 70.9 ± 229.1 mg g À1 Cr after 24 weeks. The brain natriuretic peptide and high-sensitivity C-reactive protein showed declining trends with treatment, but the overall change was not significant because of the marked differences among individuals (Table 1) . There were no significant differences in general biochemical test values or electrolytes, but fasting serum triglycerides were significantly decreased after eplerenone treatment (from 173±91 to 139 ± 59 mg per 100 ml, Po0.05). The serum potassium level was 4.3 ± 0.3 mEq l À1 before starting eplerenone treatment, and showed no significant change during treatment (Table 1) There was no significant correlation between serum potassium level changes and blood pressure (data not shown). In addition, there were no significant correlations between PRA or PAC with monotherapy before eplerenone treatment, and blood pressure after eplerenone treatment (Figure 3) , showing that the antihypertensive effect of eplerenone is not affected by the patient's renin profile or pretreatment PAC values.
Adverse effects of eplerenone During 24-week treatment with eplerenone, although there were no clinically significant adverse events, seven patients developed symptoms (dizziness: 3, rash: 1, sleepiness: 1, taste disorder: 1 and gingival swelling: 1). All of these events were transient, and the patients were eventually able to continue the treatment at the same dose. No causal relationships with eplerenone could be determined.
Effects of eplerenone in hypertensive patients with metabolic syndrome
In hypertensive patients with metabolic syndrome, blood pressure was significantly reduced from 156 ± 11 to 138 ± 7 mm Hg after 4 weeks (Po0.05 vs the value before treatment), and further to 128±4 mm Hg after 24 weeks (Po0.05 vs the value before treatment). The degree of the decrease in blood pressure in this group tended to be higher than that of the non-metabolic syndrome patients. In addition, significant decreases in UAE (from 443.4 ± 704.9 to 64.5 ± 62.7 mg/g Cr) and serum triglycerides (from 223±99 to 146±64 mg per 100 ml) were also observed after a 24-week treatment with eplerenone. There were no significant changes in waist circumference after 24 weeks.
Discussion
This study shows that concomitant use of eplerenone with an ACE inhibitor or a long-acting Clinical effects of eplerenone A Sato and S Fukuda CCB in Japanese patients with essential hypertension caused potent, stable antihypertensive effect without any important adverse events. Eplerenone is extremely MR selective, but without significantly altering the serum potassium level, and there was no correlation between potassium level changes and the antihypertensive effect in this study. In addition, UAE was significantly lowered during the course of this study. Significant decreases in serum triglycerides were also observed, especially in hypertensive patients with metabolic syndrome. If this effect is reproducible, we can reasonably speculate that eplerenone may have promising effects in those patients with metabolic disorders. We would like to discuss our study from three viewpoints. The first is the antihypertensive effect of eplerenone. In Japan, eplerenone was recently approved as a drug for hypertension in November 2007. Now that it has finally become clinically available, not enough data have been accumulated. In this study, we gave 50 mg of eplerenone to patients with essential hypertension who were already receiving imidapril or amlodipine treatment without achieving adequate blood pressure control. We observed rapid and significant decreases in blood pressure both in systolic and diastolic after 4 weeks. Blood pressure was further decreased after 24 weeks. In Japan, 50 mg of eplerenone is not the highest allowed dose, but this dose achieved a sufficient antihypertensive effect when added as the second drug to an ACE inhibitor or a long-acting CCB. Decreases in diastolic pressure were especially remarkable, suggesting that eplerenone not only inhibits the renin-angiotensin-aldosterone system but might also favorably influence the metabolic system, as discussed below.
Saruta et al. 22 reported the effectiveness and safety of eplerenone in Japanese subjects. A placebo or 50, 100 or 200 mg of eplerenone was given once daily for 8 weeks, and dose-dependent decreases in blood pressure were observed. There were no clinically important adverse events, and there was not a single case of hyperkalemia or sex hormone-related adverse events. No correlation was found between the antihypertensive effect of eplerenone and the serum potassium level in this study, which is consistent with the report by Levy et al. 23 who titrated the eplerenone dose upward, administering 50, then 100 and finally 200 mg per day in 397 patients with essential hypertension until they reached the target blood pressure. They reported that there was no significant difference in serum potassium levels Clinical effects of eplerenone A Sato and S Fukuda between the responder group, who achieved diastolic pressures of o90 mm Hg, and the non-responder group, who had diastolic pressures of X90 mm Hg, for any of the eplerenone doses. They suggested that the principal antihypertensive mechanism of eplerenone is likely to be something other than a diuretic effect (action mediated by non-epithelial MR). Basic investigations have shown that eplerenone directly acts on blood vessels and improves endothelial function. 24, 25 Just as the hypertensive mechanism mediated by aldosterone and salt is complex, 5 the antihypertensive mechanism of eplerenone may also be multifaceted.
Clinical research to date has shown that eplerenone when used alone or with other major antihypertensive drugs achieves excellent antihypertensive effects. [13] [14] [15] [16] [17] [18] [19] [20] One of the intriguing properties of eplerenone is that its antihypertensive effect is not compromised in low-renin hypertensive patients, which means that it reduces blood pressure independently of the patient's renin profile. [14] [15] [16] 26 This property makes eplerenone effective for Japanese patients who tend to have high salt intake. 27 A low salt diet is the basis of antihypertensive treatment, and instruction to maintain low salt intake needs to be repeated consistently. However, in reality, very few patients have been successful in reducing salt intake to the guideline target of 6 g per day and, recently, the daily salt intake of Japanese has averaged 11-12 g per day. 27 We should make good use of this property of eplerenone, which may exert a stable antihypertensive effect, in the treatment of Japanese hypertensive patients in whom the dietary salt control is difficult.
Saruta et al. 22 reported that the daily administration of eplerenone to Japanese patients, most of whom had low renin levels, significantly reduced both casual and 24-h blood pressures. Prisant et al. 26 examined the effects of eplerenone when added to an ACE inhibitor or an angiotensin receptor blocker (ARB) alone, including the possible association between baseline renin levels and the antihypertensive effect. No association between the antihypertensive effect and baseline plasma active renin was found, showing that the antihypertensive effect of eplerenone is independent of renin activity. Weinberger et al. 16 explored the antihypertensive effect of eplerenone and the ARB losartan in low-renin hypertensive patients. Eplerenone showed a stable antihypertensive effect regardless of the baseline active renin concentration, whereas the antihypertensive effect of losartan correlated with the active renin concentration. Flack et al. 15 further compared the efficacies of eplerenone and losartan in African Americans with typical low-renin hypertension and Caucasians with normal to high-renin hypertension. The two drugs produced similar degrees of blood pressure reduction in Caucasians, although eplerenone exerted a significantly greater degree of blood pressure reduction in African-American hypertensive patients. The antihypertensive effect of losartan is weaker in African Americans with low-renin hypertension than in Caucasian patients, although eplerenone reduced blood pressure independently of renin profiles.
The second point of discussion is the safety of eplerenone and the possible adverse events. Seven patients developed symptoms in this study. All were transient, and the patients were eventually able to continue the treatment at the same dose. According to the report of Croom et al. 28 adverse events associated with eplerenone treatment were not specific, and did not differ greatly from those of the placebo group. Eplerenone is extremely MR selective compared with spironolactone. 29, 30 As it is more than 10 times less specific to progesterone receptors and more than 100 times less specific to androgen receptors, virtually no adverse endocrine events are observed. Many placebo-controlled studies have also reported that there is no significant difference in adverse endocrine events. Therefore, eplerenone is a drug for which a sufficient antihypertensive dose can be maintained for an extended period of time. When studies were conducted in Japanese patients, including this study, as well as that conducted by Saruta et al., 22 not a single endocrine adverse event was observed. The hormone-related side effects, however, should be examined by further extending the observation period.
In addition, as eplerenone is a weaker MR antagonist compared with spironolactone at the dose we used to reduce blood pressure, its influence on serum potassium levels is slightly different. In Japan, we can generally start with 50 mg of eplerenone daily in patients with hypertension, and increase the dose to a maximum 100 mg if no effect is achieved at the lower dose. When we combine these observations with the data from overseas and look at the influence of eplerenone on serum potassium levels at this dose, no dose-dependent changes in potassium levels are ever seen within this range. 21 White et al. 17 conducted a placebocontrolled study to determine the antihypertensive effects of eplerenone at 25, 50, 100 and 200 mg per day in 310 patients with essential hypertension. After 12 weeks of treatment, one patient each from the placebo and eplerenone 200 mg groups developed hyperkalemia of X5.5 mEq l À1 , but the authors concluded that the increased dose of eplerenone was not associated with the serum potassium increase. Flack et al. 15 compared the antihypertensive effect and safety of eplerenone (starting with 50 mg and allowing increases up to 200 mg) with those of losartan and a placebo in patients with mild-to-moderate essential hypertension. The frequency of hyperkalemia was 0.6% in the placebo group, and 1.1% in the eplerenone group, not a statistically significant difference. They reported that the frequency of hyperkalemia of 5.5 mEq l À1 or higher did not differ among the three groups. In the study of Hollenberg et 16 also showed that the frequency of hyperkalemia after 16 weeks of treatment with eplerenone, at doses of 100-200 mg per day, in lowrenin hypertensive patients was not different from that of the ARB losartan.
It is widely recognized that when renal function is normal, 50-100 mg per day of eplerenone does not significantly raise potassium even if coadministered with a renin-angiotensin system inhibitor (ACE inhibitor and ARB). 19 Therefore, among the adverse events involving hyperkalemia due to eplerenone, renal impairment is the one requiring the most attention. This point should always be kept in mind. Furthermore, close attention, especially when renin-angiotensin system inhibitors are used concomitantly, is necessary. 32 The last point is that eplerenone also may be effective in hypertensive patients with metabolic syndrome. Not only a antihypertensive effect but also a significant decrease in UAE and a decrease in serum triglycerides, were observed in this study. Metabolic syndrome, especially adipocytokines secreted from pathological adipocytes and aldosterone, seem to have mutual physiological effects, and both are important to understanding the pathology of obesity, hypertension and metabolic syndrome. [33] [34] [35] [36] [37] The adipose tissue is fundamentally rich in glucocorticoid receptors coexisting with 11b-hydroxysteroid dehydrogenase type 1 (11-HSD1), and has been believed to be the glucocorticoid target tissue. [38] [39] [40] However, recently, adipose tissue was reported to also contain MR, 41 although much remains to be elucidated, including the role of MR in adipose tissue and its physiological ligands. Tallec et al. 41 reported MR involvement in the differentiation of adipose tissues. Caprio et al. 42 studied MR-mediated adipogenesis in brown adipocytes, and reported increased MR gene expression in the differentiation process of pre-adipocytes. These reports suggest the involvement of MR in adipocyte differentiation, as well as in metabolic syndrome. Henceforth, the results of clinical studies of eplerenone in human subjects are anticipated. Furthermore, obese hypertensive patients reportedly had a greater degree of decrease in blood pressure with a low salt diet than nonobese patients. They also had increased salt sensitivity, and their urine albumin excretion rose as salt intake increased. 43, 44 Obese hypertensive patients often have salt-sensitive hypertension, for which eplerenone is theoretically anticipated to be highly effective.
In conclusion, eplerenone, when coadministered with an ACE inhibitor or a long-acting CCB, caused an extremely beneficial antihypertensive effect in Japanese patients with essential hypertension, without few clinically important adverse events. Eplerenone does not significantly increase serum potassium levels in hypertensive patients without complications, but proper use is important for maintaining potassium homeostasis. Evaluation of the renal function is the most important aspect of the appropriate use of eplerenone and careful attention is always required both before and during eplerenone treatment.
